ASH 2021 | Tabelecleucel as an alternative treatment option in patients following transplantation
AJ Joshi
• 22 Dec 2021
AJ Joshi, MD, Atara Biotherapeutics, San Francisco, CA, discusses alternative treatment options for patients who undergo solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT), where chemotherapy is not well-tolerated or viable. Dr Joshi mentions the use of rituximab as a standard method of treatment, and then goes on to discuss the need for other treatment options when rituximab fails, drawing focus on tabelecleucel. Dr Joshi also explains the importance of considering the overall safety profile of alternative therapies such as tabelecleucel, including cytokine release syndrome and neurotoxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
